



August , 2016  
FOR 8:30 AM RELEASE  
CSE:GCI

## ***PhytoPain Pharma Announces Appointments to its Scientific and Clinical Advisory Board***

Ottawa, Ontario - (Marketwired – August , 2016) – PhytoPain Pharma Inc. (“**PhytoPain Pharma**” or “**PPP**”), a subsidiary of GrowPros Cannabis Ventures Inc. (“**GrowPros**” or the “**Company**”) (CSE:GCI), is pleased to announce the creation of its Scientific and Clinical Advisory Board. The board is comprised of experts in clinical research, pain management as well as cancer and neurological product drug development. The Advisory Board will provide strategic guidance on PPP’s clinical development program, clinical trial designs, and pipeline of preclinical and clinical candidates for the treatment of pain, insomnia and other conditions affecting cancer patients. “This team of accomplished scientific and clinical experts will collaborate with us on our goal of bringing these new prescription drug products to patients while addressing the concerns of the medical establishment and regulators,” stated Dr. Chamberland, Chief Scientific Officer and Regulatory Affairs.

The President of the board will report directly to the Board of Directors of GCI. The advisory board is expected to meet before the end of October to review the clinical development plan of PPP’s phase I clinical study of smoked cannabis and the development of future cannabis-based therapeutics. PPP intends on submitting the Clinical Trial Application (CTA) after incorporating the recommendations obtained from its expert advisory panel into the clinical development program. PPP also intends on submitting the clinical protocol to the US Food & Drug Administration (FDA) for review. PPP is developing this prescription drug product for both the Canadian and USA market and intends on obtaining approval from Health Canada and the US FDA.

"We are honored to have these distinguished experts join GCI's new advisory board," said Ryan Brown CEO of GCI. "We are enlisting these experts to assist PPP in developing prescription drugs for patients suffering from uncontrolled pain."

The President of the Advisory Board is Dr. Luc Vachon, Ph.D. Dr. Vachon has more than 25 years of experience in drug development. He has worked in two multinational

pharmaceutical organizations, a CRO, and two “biotech” companies. He has held various positions, including Global Product Team Leader, Executive V.-P. of R&D, CEO and president, and has also been teaching in the academia. He is presently active as independent consultant in drug development.

Dr. André Bélanger, MD is a member of the pain clinic at the Hôtel-Dieu de Lévis and at Clinique Médicale Valcartier. He is a recognized medical expert in pain management and provides continuing education on pain management for multiple provincial and national programs.

**Dr. Gordon D. Ko** MD, CCFP(EM), FCFP, FRCPC [www.DrKoPRP.com](http://www.DrKoPRP.com) is a specialist in Physical Medicine and Rehabilitation (Physiatry) with subspecialty in Pain Medicine. He is former Senior University Associate Professor and current Medical Director, Interventional Physiatry clinics and Adjunct Lecturer at Sunnybrook Health Sciences Centre, University of Toronto and the Canadian Centre for Integrative Medicine (Markham). His expertise with Platelet-rich Plasma (PRP) for Back Pain and Botox injections for Osteoarthritis made headline CTV national news. With over 25 years experience in treating Fibromyalgia(FMS) and chronic neuropathic pain (including Cannabinoids, Functional Medicine), he was selected on the Canadian Pain Society committee that developed new guidelines (2012) for FMS management. More recently, he was lead author for a peer-reviewed review paper (J Pain Research 2016) on Medical Cannabis: a Canadian Perspective.

Dr. Pierre Arsenault, Ph.D., M.D., CPI is a family medicine practitioner and pain management expert and is an associate professor of family medicine at Université de Sherbrooke. He has a vast experience in clinical research and is a Clinical Physician Investigator (CPI) at DIEX Research.

**For further information, please contact GrowPros Cannabis Ventures Inc.**

Ryan Brown	André Audet	Dr. Guy Chamberland
Chief Executive Officer	Executive Chairman	Chief Scientific Officer and Regulatory Affairs
Phone: (613) 421-8402	Phone: (613) 421-8402	Phone: (514) 220-9225

*The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.*

**Forward-looking statements**

*Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential*

acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.